LC
Therapeutic Areas
Lexicon Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| INPEFA (sotagliflozin) | Heart Failure | Approved |
| LX9211 | Diabetic Peripheral Neuropathic Pain (DPNP) | Phase 2 |
| Sotagliflozin | Type 1 Diabetes | Phase 3 |
Leadership Team at Lexicon Pharmaceuticals
JL
Jeffrey L. Wade
President, Chief Financial Officer & Corporate Strategy
CA
Craig A. Granowitz, M.D., Ph.D.
Senior Vice President & Chief Medical Officer
AJ
Alan J. Main, Ph.D.
Executive Vice President, Pharmaceutical Research & Development
BT
Brian T. Crum, M.D.
Senior Vice President, Commercial